NCT07427680 Study of TGM-312-SC01 in Healthy Participants and Adults With MASH
| NCT ID | NCT07427680 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Tangram Therapeutics Plc |
| Condition | Healthy Participants |
| Study Type | INTERVENTIONAL |
| Enrollment | 99 participants |
| Start Date | 2026-03-03 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 99 participants in total. It began in 2026-03-03 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of single ascending doses of TGM-312-SC01 in healthy adults and multiple ascending doses in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 70 years who are able to provide written informed consent. * Medically suitable for study participation based on protocol-defined assessments. * For the disease cohort, participants with clinical features consistent with metabolic dysfunction-associated steatohepatitis, as defined in the protocol. Exclusion Criteria: * Clinically significant medical conditions, laboratory abnormalities, or other findings that, in the opinion of the investigator, could increase risk, interfere with study participation, or confound interpretation of study results. * Recent participation in another investigational study. * Use of medications that are prohibited by the protocol. * Any other condition that would make the individual unsuitable for study participation as determined by the investigator.
Contact & Investigator
Sponsor Medical Representative
STUDY DIRECTOR
Tangram Therapeutics
Frequently Asked Questions
Who can join the NCT07427680 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Healthy Participants. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07427680 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07427680 currently recruiting?
Yes, NCT07427680 is actively recruiting participants. Contact the research team at clinicaltrials@tangramtx.com for enrollment information.
Where is the NCT07427680 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT07427680 clinical trial?
NCT07427680 is sponsored by Tangram Therapeutics Plc. The principal investigator is Sponsor Medical Representative at Tangram Therapeutics. The trial plans to enroll 99 participants.